[(2R)-2,3-二(二十三烷酰基氧基)丙基]2-三甲基铵乙基磷酸酯盐 | 112241-60-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: [(2R)-2,3-二(二十三烷酰基氧基)丙基]2-三甲基铵乙基磷酸酯盐
• 英文名称: 1,2-Ditricosanoyl-sn-glycero-3-phosphocholine
• 英文别名: [(2R)-2,3-di(tricosanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 112241-60-8
• 化学式: C54H108NO8P
• 分子量: 930.4
• InChiKey: XGMMADXONKETMF-OIVUAWODSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  21
• 重原子数：
  64
• 可旋转键数：
  54
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• WGK Germany：
  3

文献信息

• Compositions and methods for enhancing contrast in imaging
  申请人：Marval Biosciences, Inc.

  公开号：EP2578237A1

  公开（公告）日：2013-04-10

  Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast- enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making liposomes containing high concentrations of contrast-enhancing agents, and example methods for using the compositions.

  本发明提供了一些脂质体组合物实例，这些脂质体表面具有亲水性聚合物，并含有相对高浓度的计算机断层扫描造影剂。这种脂质体的药物组合物范例在给受试者用药时，可使受试者血液和其他组织中的对比度增加，持续时间延长，如计算机断层扫描所测。此外，还提供了制造含有高浓度造影剂的脂质体的示例方法，以及使用这些组合物的示例方法。
• Liposomal formulation of nonglycosidic ceramides and uses thereof
  申请人：LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.

  公开号：US10039715B2

  公开（公告）日：2018-08-07

  The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.

  本发明提供了在其双层内含有非糖苷类神经酰胺的脂质体及其组合物。这些脂质体可在体外和体内激活小鼠 iNKT 细胞并诱导树突状细胞（DC）成熟，其功效与相应的可溶性非糖苷神经酰胺相当。此外，还提供了使用本发明脂质体和组合物治疗疾病的方法。
• Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
  申请人：ModernaTX, Inc.

  公开号：US10172808B2

  公开（公告）日：2019-01-08

  The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

  本公开涉及免疫调节多核苷酸（如mRNA）编码免疫应答引物多肽（如白细胞介素23（IL-23）多肽或白细胞介素36γ（IL-36-γ）多肽）和免疫应答共刺激信号多肽（如OX40L多肽）组合的制备、制造和治疗使用的组合物和方法。
• MRNA combination therapy for the treatment of cancer
  申请人：ModernaTX, Inc.

  公开号：US10335486B2

  公开（公告）日：2019-07-02

  The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.

  本公开涉及使用核酸（如mRNA）组合疗法治疗癌症。本公开提供了组合物及其制备、制造和治疗使用的方法，其中这些组合物包括至少两种组合在一起的多核苷酸（如mRNA），其中至少两种多核苷酸选自由以下组成的组(i)编码免疫应答引物的多核苷酸（如IL23），(ii)编码免疫应答引物的多核苷酸（如IL23），(iii)编码免疫应答引物的多核苷酸（如IL23），(iv)编码免疫应答引物的多核苷酸（如IL23）、IL23），(ii) 编码免疫应答共刺激信号（如 OX40L）的多核苷酸，(iii) 编码检查点抑制剂（如抗 CTLA-4 抗体）的多核苷酸，以及 (iv) 其组合。本文公开的治疗方法包括，例如，在有需要的受试者中施用本文公开的用于治疗癌症的组合疗法，例如，通过减小肿瘤大小或抑制肿瘤生长。在某些方面，本文公开的组合疗法是肿瘤内给药。
• Polynucleotides encoding methylmalonyl-CoA mutase
  申请人：ModernaTX, Inc.

  公开号：US10406112B2

  公开（公告）日：2019-09-10

  The disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human methylmalonyl-CoA mutase precursor, human methylmalonyl-CoA mutase (MCM) mature form, or functional fragments thereof. In some embodiments, the disclosure includes methods of treating methylmalonic acidemia in a subject in need thereof comprising administering an mRNA encoding an MCM polypeptide.

  本公开涉及多核苷酸，其包含编码人甲基丙二酰-CoA 突变酶前体、人甲基丙二酰-CoA 突变酶（MCM）成熟形式或其功能片段的连接核苷酸开放阅读框。在一些实施方案中，本公开包括治疗有需要的受试者的甲基丙二酸血症的方法，包括给药编码 MCM 多肽的 mRNA。